USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: APOIMMUNE, INC
Address: APOIMMUNE, INC
1044 E CHESTNUT ST
LOUISVILLE, KY 40204
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,393,963.00 5
SBIR Phase II $1,636,799.00 1
STTR Phase I $428,300.00 2

Award List:

A NOVEL APPROACH TO PREVENT GRAFT-VERSUS HOST DISEASE

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: G. D. Mcclure
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by the applicant): Bone marrow transfusion (BMT) holds the potential to cure many blood diseases. However, BMT recipients often develop graft-versus-host disease (GvHD), a life-threatening condition in which immune cells from the infused transplant attack the recipient's… More

A NOVEL ADJUVANT FOR TUMQR VACCINATION

Award Year / Program / Phase: 2004 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF LOUISVILLE
Principal Investigator: Haval Shirwan
Award Amount: $100,000.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Cancer continues to be a leading cause of death in the U.S. and in many other countries. Cancers develop and spread within the body when tumor cells are not detected or destroyed by the immune system. Although certain new therapies hold promise, current cancer… More

Chimeric CD80-SA as a Novel Cancer Vaccine

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rolf M. Huseby
Award Amount: $750,804.00
Abstract:
DESCRIPTION (provided by applicant): Cancer is one of the major causes of death in the U.S. and many developed countries with an estimated economic burden of over 100 billion dollars in direct and indirect costs in the U.S. alone. Although surgery, chemotherapy, and radiotherapy are commonly used… More

ApoFasL: a Novel Immunotherapeutic for T1D

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $421,676.00
Abstract:
DESCRIPTION (provided by applicant): Type 1 Diabetes (T1D) is an autoimmune disease that targets insulin secreting pancreatic beta cells for destruction and remains a major cause of morbidity and mortality in over 1% of the population worldwide. Although i nsulin therapy and islet transplantation… More

ApoVax-SVN as a Novel Vaccine for Cancer Immunotherapy

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF LOUISVILLE
Principal Investigator: Haval Shirwan
Award Amount: $328,300.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The main objective of this proposal is to develop a novel cancer vaccine, ApoVax-SVN(tm) based on the use of a proprietary costimulatory chimeric ligand, 4-1BBL, designed to specifically deliver survivin, a tumor associ ated antigen (TAA) to professional… More

ApoVax104-HPV as a Novel Vaccine for Cervical Cancer

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kathryn J. Macleod
Award Amount: $300,000.00
Abstract:
DESCRIPTION (provided by applicant): Various cancer vaccines based on tumor associated antigens (TAAs) or tumor specific antigens (TSAs) have shown efficacy in preclinical models. However, their therapeutic efficacies have been rather limited in clinical trial settings. Although the reason for… More

ApoVax104-HPV as a Novel Vaccine for Cervical Cancer

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: Kathryn J. Macleod
Award Amount: $1,636,799.00
Abstract:
DESCRIPTION (provided by applicant): Cervical cancer is one of the most common cancers affecting women and is a worldwide health problem. Unlike most cancers, cervical cancer is caused by a virus - the human papillomavirus (HPV). Two preventative vaccines against HPV were recently licensed in the… More

ApoVax104-TB as a Novel Vaccine for Tuberculosis

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kathryn J. Macleod
Award Amount: $821,483.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this NIAID Advanced STTR Phase I proposal is to combine the strengths of academic investigators from the fields of immunology and animal disease modeling with the resources of ApoImmune Inc. to develop a novel vaccine, ApoVax104-TB targeting… More